<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927781</url>
  </required_header>
  <id_info>
    <org_study_id>2013680</org_study_id>
    <nct_id>NCT03927781</nct_id>
  </id_info>
  <brief_title>Perioperative Pregabalin in Ureteroscopy: a Pilot</brief_title>
  <official_title>Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a pilot clinical trial on the use of perioperative pregabalin in
      order to decrease ureteral stent related symptoms and decrease opioid usage after
      ureteroscopy with stent placement. Patients undergoing ureteroscopy with stent placement will
      receive a single dose of 300 mg pregabalin PO in the preoperative area. This work will assess
      safety and feasibility of studying this regimen at our institution, with the aim of
      performing a randomized, placebo-controlled, double-blinded study in the future.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">October 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will receive 300mg PO pregabalin one hour before procedure start</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>There will be no blinding for this pilot</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events related to study drug</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Adverse events related to study drug, mainly in post anesthesia care unit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Administration of study drug</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Verified correct administration of study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respondent reported usability of instruments</measure>
    <time_frame>30 days post-op</time_frame>
    <description>Questionnaire respondent self-report of usability of instrument</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early post-op stent related symptoms</measure>
    <time_frame>Post-op day 3</time_frame>
    <description>Ureteral Stent Related Symptom Questionnaire (USSQ) score.
Subscores include the following:
Urinary Index Score (11-57). Higher scores indicates worse outcomes. Pain Index Score (6-30) Higher scores indicates worse outcomes. General Health Index Score (6-30). Higher scores indicates worse outcomes. Work Performance Score (3-15). Higher scores indicates worse outcomes. Sexual Matters( 2-10) Higher scores indicates worse outcomes. Additional Problems with the stent in situ (4-17) Higher scores indicates worse outcomes.
Global Quality of life with the stent in situ (1-7). Higher scores indicates worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early post-op opioid needs</measure>
    <time_frame>First 30 post-operative days</time_frame>
    <description>Monitored prescribing of narcotic pain medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use</measure>
    <time_frame>Up to 1 year post-op</time_frame>
    <description>Opioid use for any indication at several time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of opioid use</measure>
    <time_frame>Up to 1 year post-op</time_frame>
    <description>Amount of opioid used for any indication at several time points, in oral morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned healthcare contacts</measure>
    <time_frame>First 30 post-operative days</time_frame>
    <description>Number of unplanned contacts between the patient and the healthcare system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>First 30 post-operative days</time_frame>
    <description>Score on standardized evaluation of patient satisfaction at various time points. There are two questions graded from very dissatisfied to very satisfied regarding pain related satisfaction and overall satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Nephrolithiasis</condition>
  <condition>Urolithiasis</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Pain, Acute</condition>
  <condition>Anesthesia</condition>
  <condition>Urologic Diseases</condition>
  <condition>Anesthesia Morbidity</condition>
  <arm_group>
    <arm_group_label>Pregabalin 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg pregabalin, PO, once, 1 hr before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 300mg</intervention_name>
    <description>One 300mg capsule will be administered PO 1 hour before surgery</description>
    <arm_group_label>Pregabalin 300mg</arm_group_label>
    <other_name>Lyrica</other_name>
    <other_name>Gabapentinoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Population Undergoing elective ureteroscopy with stent placement by Dr. Murray at
        University of Missouri Hospital and affiliated facilities

        Subject Inclusion

        Age &gt;= 18 years

        Subject Exclusion

          -  Renal insufficiency (eGFR &lt; 30 mL/minute/1.73 m2)

          -  Chronic indwelling ureteral stent

          -  Chronic opioid use

          -  History of opioid abuse

          -  Chronic gabapentinoid use

          -  Plan for inpatient hospitalization

          -  Pregnancy

          -  Inability of the patient to consent for themselves in English

          -  Allergy to gabapentinoid

          -  Liver failure or hepatic dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katie Murray, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Missouri-Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Katie Murray</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Pregabalin</keyword>
  <keyword>Perioperative medicine</keyword>
  <keyword>Opioid sparing</keyword>
  <keyword>Urolithiasis</keyword>
  <keyword>Ureteroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03927781/Prot_ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03927781/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

